This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Neurocrine Biosciences, Inc.
Drug Names(s): NBI-34060-MR, Indiplon MR tablets
Description: BioMedTracker has separate drug profiles for the XR and IR formulationsof Indiplon. Please also see Indiplon-IR.
Indiplon is a non-benzodiazepine sedative-hypnotic that targets a specific GABA-A receptor site. Currently marketed non-benzodiazepine sedative-hypnotics also promote sleep via this mechanism of action. Indiplon is most similar to Sanofi-Synthélabo’s Ambien (zolpidem) and Élan & Wyeth’s Sonata (zaleplon), both of which have been successful as prescription sleep medications.
Neurocrine is developing both immediate release (IR) and modified release (MR) formulations of indiplon.
Deal Structure: In July 1998, Neurocrine gained exclusive rights to develop indiplon worldwide from DOV Pharmaceuticals, Inc. Neurocrine made an equity investment in DOV, and will pay milestones and royalties to DOV.
In February, 2004 Neurocrine purchased all of Wyeth's financial interest in indiplon. Neurocrine retained all milestone, royalty and other payments on indiplon commercialization that would have otherwise been payable to Wyeth. The transaction also provided Neurocrine ownership and control over the indiplon composition of matter patent which expire in 2020.
The transaction was valued at approximately $95 million, with $50 million payable in cash and $45 million payable in Neurocrine common stock. The indiplon royalty obligations of six percent were reduced to three and one-half percent.
Neurocrine partnered with Pfizer in December 2002 to develop and promote indiplon worldwide.
June 22, 2006 - Neurocrine announced it agreed with Pfizer to terminate co-development and...See full deal structure in Biomedtracker
Partners: Euthymics Bioscience, Inc. Sumitomo Dainippon Pharma Co., Ltd.
Indiplon XR News
Additional information available to subscribers only: